(OA13) Stereotactic Radiosurgery and Concurrent Targeted Therapy: Improving the Response Rate for Breast Cancer Brain Metastasis

The use of HER2-directed monoclonal antibodies has changed the landscape of patients with HER2-positive breast cancer. Despite the increase in overall survival with the use of agents such as trastuzumab, the drug's poor penetration through the blood-brain barrier leaves the brain particularly vulnerable to disease relapse. In contrast, lapatinib, a dual HER2/EGFR small molecule tyrosine kinase inhibitor (TKI), has demonstrated greater penetration through the blood brain barrier, but evidence of its clinical use in patients with CNS metastases is limited.

https://ift.tt/2HK5JZp